Picture loading failed.

Anti-pro-GDF-8 therapeutic antibody (Pre-made Apitegromab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Apitegromab (SRK 015) is an anti-promyostatin monoclonal antibody that is being developed by Scholar Rock, for the treatment of spinal muscular atrophy (SMA), muscle-wasting disorders and spinal cord injuries.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-030-1mg 1mg 3090
GMP-Bios-ab-030-10mg 10mg 21890
GMP-Bios-ab-030-100mg 100mg 148000
GMP-Bios-ab-030-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-pro-GDF-8 therapeutic antibody (Pre-made Apitegromab biosimilar,Whole mAb)
INN Name Apitegromab
Targetpro-GDF-8
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure6umx:HL:hl
Year Proposed2020
Year Recommended2021
CompaniesScholar Rock
Conditions Approvedna
Conditions ActiveSpinal muscular atrophy;Muscular atrophy;Spinal cord injuries
Conditions Discontinuedna
Development Techna